Recombinant Rat Tnfrsf18 protein, Fc-tagged
Cat.No. : | Tnfrsf18-8735R |
Product Overview : | Recombinant Rat Tnfrsf18 (Gln20-Lys121) protein was fused to human IgG1 Fc tag at C-terminus and expressed in human 293 cells (HEK293). |
Availability | February 11, 2025 |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
- Download
Description : | Glucocorticoid-induced TNFR-related protein (GITR) is also known as Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), activation-inducible TNFR family receptor (AITR), CD antigen CD357, which is a member of the tumor necrosis factor receptor (TNF-R) superfamily. GITR is receptor for TNFSF18, which seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. GITR also mediated NF-kappa-B activation via the TRAF2/NIK pathway. |
Source : | HEK293 |
Species : | Rat |
Tag : | Fc |
Predicted N Terminal : | Gln20 |
Form : | Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5, 10% trehalose. |
Molecular Mass : | The protein has a calculated MW of 37.2 kDa. The protein migrates as 45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. |
Protein length : | Gln20-Lys121 |
Endotoxin : | Less than 1.0 EU per μg by the LAL method. |
Purity : | >95% as determined by SDS-PAGE. |
Storage : | For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: -20 to -70 centigrade for 12 months in lyophilized state; -70 centigrade for 3 months under sterile conditions after reconstitution. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name : | Tnfrsf18 |
Official Symbol : | Tnfrsf18 |
Synonyms : | TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18 |
Gene ID : | 500598 |
mRNA Refseq : | NM_001024349 |
Protein Refseq : | NP_001019520 |
UniProt ID : | F7FFS7 |
Products Types
◆ Recombinant Protein | ||
TNFRSF18-663M | Recombinant Mouse TNFRSF18 Protein, Fc-tagged | +Inquiry |
TNFRSF18-894M | Recombinant Mouse TNFRSF18 Protein (Met1-His153), MlgG1 Fc-tagged | +Inquiry |
TNFRSF18-661H | Recombinant Human TNFRSF18 Protein | +Inquiry |
Tnfrsf18-666R | Recombinant Rhesus macaque Tnfrsf18 Protein, Fc-tagged | +Inquiry |
TNFRSF18-154H | Recombinant Human TNFRSF18 Protein, C-His-tagged | +Inquiry |
◆ Lysates | ||
TNFRSF18-1143HCL | Recombinant Human TNFRSF18 cell lysate | +Inquiry |
TNFRSF18-1245RCL | Recombinant Rat TNFRSF18 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThis flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.
Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.
The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.
Q&As (5)
Ask a questionClinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.
As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.
Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.
TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.
Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.
Ask a Question for All Tnfrsf18 Products
Required fields are marked with *
My Review for All Tnfrsf18 Products
Required fields are marked with *
Inquiry Basket